Discontinued drugs in 2010: oncology drugs

被引：12
|
作者：
Williams, Robert [1 ]
机构：
[1] Canc Res UK, Drug Dev Off, London EC1V 4AD, England
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 11期
关键词：
Ad-IFN gamma; amsilarotene; AR-726; aroplatin; ASP-0265; AZD-0530; bardoxalone; BIM-23A760; CGP-47905; CP-870893; drozitumab; efungumab; galiximab; GDC-0152; golgnerminogene pradenovac; GSK-184072; IDEC-114; JNJ-26854165; KW-2449; MYC-124; neuradiab; NRX-4204; patupilone; PF-3814735; PF-477736; PF-4929113; PF-5208766; resveratrol; RG-4733; RG-7419; RG-7425; RTA-401; saracatinib; serdemetan; SGI-1776; SRT-501; SU-14813; TAC-101; TAK-683; TAS-109; TG-1042; TNFerade; KINASE;
D O I：
10.1517/13543784.2011.623697
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The Pharmaceutical Industry is currently undergoing a period of rapid change as the pressures of the financial markets highlight fundamental inefficiencies in the current business model. The Achilles heel for the industry is the unacceptable level of attrition in clinical drug development. An imperative for the industry is to reduce the cost and increase the efficiency of Research and Development (R&D). This article provides an analysis of cancer drugs dropped from the industry pipeline in 2010 and offers a perspective on how the future oncology drug pipeline might evolve.
引用
收藏
页码：1479 / 1496
页数：18
相关论文
共 50 条
12345